Where companies traditionally have had to jump through hoops to impress regulators to approve the drugs they develop, they will
increasingly find themselves jumping through even narrower hoops to convince payors that they have made significant strides in improving patient care.
have been somewhat of an urban legend in the pharma/biotech industries for almost as long as I have been alive. Despite how far we’ve come and how far we’ve
yet to go, we’re reporting some stories this month that suggest genetic medicine may not be as science fiction-y as it seems.